224 related articles for article (PubMed ID: 22806877)
21. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Inhibition of Hsp90 Protein by Benzothiazoloquinazolinequinones Is Enhanced in The Presence of Ascorbate. A Preliminary In Vivo Antiproliferative Study.
Valderrama JA; Ríos D; Muccioli GG; Buc Calderon P; Benites J
Molecules; 2020 Feb; 25(4):. PubMed ID: 32093392
[TBL] [Abstract][Full Text] [Related]
23. 9,10-Dioxoanthracenyldithiocarbamates effectively inhibit the proliferation of non-small cell lung cancer by targeting multiple protein tyrosine kinases.
Olszewski M; Stasevych M; Zvarych V; Maciejewska N
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2284113. PubMed ID: 38078360
[TBL] [Abstract][Full Text] [Related]
24. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers.
Mijatovic T; Mathieu V; Gaussin JF; De Nève N; Ribaucour F; Van Quaquebeke E; Dumont P; Darro F; Kiss R
Neoplasia; 2006 May; 8(5):402-12. PubMed ID: 16790089
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer.
Shang FF; Lu Q; Lin T; Pu M; Xiao R; Liu W; Deng H; Guo H; Quan ZS; Ding C; Shen QK
J Med Chem; 2023 Sep; 66(18):12931-12949. PubMed ID: 37681508
[TBL] [Abstract][Full Text] [Related]
26. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.
Salim KY; Maleki Vareki S; Danter WR; Koropatnick J
Oncotarget; 2016 Jul; 7(27):41363-41379. PubMed ID: 27150056
[TBL] [Abstract][Full Text] [Related]
27. Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition.
Vriend LEM; van den Tempel N; Oei AL; L'Acosta M; Pieterson FJ; Franken NAP; Kanaar R; Krawczyk PM
Oncotarget; 2017 Nov; 8(57):97490-97503. PubMed ID: 29228626
[TBL] [Abstract][Full Text] [Related]
28. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Socinski MA; Goldman J; El-Hariry I; Koczywas M; Vukovic V; Horn L; Paschold E; Salgia R; West H; Sequist LV; Bonomi P; Brahmer J; Chen LC; Sandler A; Belani CP; Webb T; Harper H; Huberman M; Ramalingam S; Wong KK; Teofilovici F; Guo W; Shapiro GI
Clin Cancer Res; 2013 Jun; 19(11):3068-77. PubMed ID: 23553849
[TBL] [Abstract][Full Text] [Related]
29. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
Goldman JW; Raju RN; Gordon GA; El-Hariry I; Teofilivici F; Vukovic VM; Bradley R; Karol MD; Chen Y; Guo W; Inoue T; Rosen LS
BMC Cancer; 2013 Mar; 13():152. PubMed ID: 23530663
[TBL] [Abstract][Full Text] [Related]
30. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
Lazenby M; Hills R; Burnett AK; Zabkiewicz J
Leuk Res; 2015 Jun; 39(6):617-24. PubMed ID: 25882550
[TBL] [Abstract][Full Text] [Related]
31. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
Goyal L; Wadlow RC; Blaszkowsky LS; Wolpin BM; Abrams TA; McCleary NJ; Sheehan S; Sundaram E; Karol MD; Chen J; Zhu AX
Invest New Drugs; 2015 Feb; 33(1):128-37. PubMed ID: 25248753
[TBL] [Abstract][Full Text] [Related]
32. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
33. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
[TBL] [Abstract][Full Text] [Related]
34. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G
Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505
[TBL] [Abstract][Full Text] [Related]
35. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
36. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
37. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
[TBL] [Abstract][Full Text] [Related]
38. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90 inhibitors in non-small-cell lung cancer.
Pillai RN; Ramalingam SS
Curr Opin Oncol; 2014 Mar; 26(2):159-64. PubMed ID: 24463348
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.
Taipale M; Krykbaeva I; Koeva M; Kayatekin C; Westover KD; Karras GI; Lindquist S
Cell; 2012 Aug; 150(5):987-1001. PubMed ID: 22939624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
